This document provides guidance to industry on good pharmacovigilance practices and pharmacoepidemiologic assessment of observational data regarding drugs, including biological drug products (excluding blood and blood components). Specifically, this document provides guidance on:

1. Safety signal identification
2. Pharmacoepidemiologic assessment and safety signal interpretation, and
3. Pharmacovigilance plan development.

[View PDF]